• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Independent Forecasts and Competitive Intelligence on Turkey's Pharmaceuticals and Healthcare Industry Out Now

Posted on: Friday, 11 July 2008, 09:01 CDT

Research and Markets (http://www.researchandmarkets.com/research/a65da8/turkey_pharmaceuti) has announced the addition of the "Turkey Pharmaceuticals and Healthcare Report Q2 2008" report to their offering.

The Turkey Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Turkeys pharmaceuticals and healthcare industry.

The Turkish pharmaceutical market is set to increase in value from an estimated US$7.9bn to US$12.5bn in 2012. The introduction of the new universal health insurance system, a landmark in the development of the Turkish health sector, will be a considerable factor in helping the industry modernise. In the meantime, local production will continue to be focused on generics, with unregistered copies remaining commonplace. The domestic industry's research and development (R&D) capacity has historically been severely limited due to a lack of investment. However, this is likely to change, with foreign interest in the form of increased acquisition activity already in evidence.

For Q208, BMI's Business Environment Rating once again places Turkey in second place, below only the United Arab Emirates (UAE). While its commercial potential is boosted by a large and expanding population, stringent price controls, an unstable political environment and deficiencies in its intellectual property (IP) regime represent key market access barriers to multinationals. Nevertheless, its geographical position between the East and the West and recent progress in membership negotiations with the European Union (EU) are increasing the country's attractiveness to foreign companies wishing to expand to new regions.

To this end, in mid-2007, Czech drugmaker Zentiva acquired a 75% stake in the generic pharmaceuticals unit of Turkish industrial conglomerate Eczacibasi. Zentiva now plans to use the local facilities to incorporate its own range of generics into its new subsidiary, with the aim of making Eczacibasi-Zentiva the country's leading generics manufacturer over the next five years. Zentiva also hopes to use the country as a regional export base - mirroring moves by major R&D-focused multinationals over recent years, including Novartis and GlaxoSmithKline (GSK).

In the meantime, the Turkish medical devices market - being the largest of its kind in the region - provides opportunities as another area of investment. Worth an estimated US$1bn, it is mostly supplied by imports from the US and the EU, which are free of duty charges. The domestic medical devices industry is developing, with its output largely exported to Germany, France, Belgium and the UK. Further integration of Turkey into the European community, healthcare sector modernisation and economic development will improve both import and export prospects for manufacturers of medical devices.

Key Topics Covered:

Executive Summary

Turkey Pharmaceuticals And Healthcare Industry SWOT

Turkey Political SWOT

Turkey Economic SWOT

Turkey Business Environment SWOT

Pharmaceutical Business Environment Rating

Limits Of Potential Returns

Risks To Realisation Of Returns

Turkey - Market Summary

Regulatory Regime

Intellectual Property Regime

Intellectual Property Shortcomings

Pricing Regime

Reimbursement Regime

Industry Developments

Health Profile

Healthcare Sector

Healthcare Expenditure

Healthcare Sector Reforms

Health Insurance

Pharmaceutical Sector

Pharmaceutical Retail and Distribution

Recent Pharmaceutical Sector Developments

International Co-operation

Research And Development Sector

Medical Devices

Overall Market Forecast

Key Growth Factors - Industry

Key Growth Factors - Macroeconomic

Patented Drug Market Forecast

Generics Market Forecast

OTC Market Forecast

Export/Import Market Forecasts

Other Healthcare Data

Competitive Landscape

Company Profiles

- Novartis

- Sanofi-Aventis

- GlaxoSmithKline

- Pfizer

- Roche

- AstraZeneca

- Bayer

- Merck & Co

- Abdi Ibrahim

- Eczacibasi Pharmaceuticals

- Sanovel Pharmaceuticals

- EastPharma (formerly Deva Holding)

- Actavis (formerly Fako)

- Biomeks

Companies Mentioned:

- Novartis

- Sanofi-Aventis

- GlaxoSmithKline

- Pfizer

- Roche

- AstraZeneca

- Bayer

- Merck & Co

- Abdi Ibrahim

- Eczacibasi Pharmaceuticals

- Sanovel Pharmaceuticals

- EastPharma (formerly Deva Holding)

- Actavis (formerly Fako)

- Biomeks

For more information visit http://www.researchandmarkets.com/research/a65da8/turkey_pharmaceuti

Source: Business Wire

More News in this Category